Indication
CDKN2A
1 clinical trial
2 products
Product
MilademetanProduct
AtezolizumabClinical trial
A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)Status: Withdrawn, Estimated PCD: 2023-05-30